Online inquiry

IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1644MR)

This product GTTS-WQ1644MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GP6 gene. The antibody can be applied in Ischemic stroke research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001083899.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51206
UniProt ID Q9HCN6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1644MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6104MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ12956MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ13635MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ14215MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ852MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ8439MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ9720MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ15517MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7858
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW